Measurable Residual Disease (MRD), also referred to as minimal residual disease, represents the small number of malignant cells that persist after therapy but remain undetectable by conventional methods such as microscopy or imaging. NGS-based MRD testing provides ultra-sensitive molecular detection of residual disease for treatment response assessment, early molecular relapse monitoring, risk stratification, therapy guidance, and longitudinal disease surveillance across hematological malignancies and solid tumors. MRD positivity may precede clinical or radiological relapse by weeks to months, supporting earlier therapeutic intervention and informed clinical decision-making
| Feature | Description | |
|---|---|---|
| High-Sensitivity Detection | Detects residual malignant cells beyond conventional diagnostic thresholds. | |
| NGS-Based MRD Assessment | Identifies clinically relevant SNVs, indels, CNVs, gene fusions, and other genomic biomarkers with high analytical sensitivity. | |
| Molecular Response Monitoring | Enables longitudinal tracking of treatment response and disease burden. | |
| Early Molecular Relapse Detection | Detects molecular relapse prior to clinical or radiological progression. | |
| Genomic Alteration Tracking | Monitors disease-associated genomic alterations and fusion transcripts. | |
| ctDNA-Based MRD Assessment | Enables non-invasive molecular monitoring in solid tumors using liquid biopsy and circulating tumor DNA (ctDNA). | |
| Baseline & Longitudinal Monitoring | Compares baseline and follow-up molecular profiles for serial MRD assessment. | |
| Post-Transplant Surveillance | Supports pre- and post-hematopoietic stem cell transplant monitoring. | |
| Prognostic & Risk Assessment | Provides prognostic insights for relapse risk assessment and therapy decision-making. |
T-MRD (T-ALL) : MGM1374 B-MRD (B-ALL) : MGM1230 Multiple Myeloma MRD by Flow Cytometry : MGM1667 Acute Myeloid Leukemia (AML) – MRD : MGM2468
TAT: 2 Working Days
Sample: Peripheral Blood or Bone Marrow Aspirate (preferred)
AML MRD by NGS – SNVs & Indels: MGM2734 AML MRD by NGS – Fusions: MGM2733 Leukemia MRD by NGS – SNVs & Indels: MGM2534 Leukemia MRD by NGS – Fusions: MGM2603
TAT: 14 Working Days
Detects residual malignant cells at very low molecular levels beyond conventional diagnostic methods.
Extensive coverage of clinically relevant SNVs, InDels, CNVs, gene fusions, MSI, TMB, and HRD-associated genomic signatures.
Supports baseline and serial molecular monitoring for treatment response assessment and early molecular relapse detection.
Please share your details to get
in touch with our experts.
